237 related articles for article (PubMed ID: 27459660)
1. Factors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression Analysis.
Farias AJ; Hansen RN; Zeliadt SB; Ornelas IJ; Li CI; Thompson B
J Manag Care Spec Pharm; 2016 Aug; 22(8):969-78. PubMed ID: 27459660
[TBL] [Abstract][Full Text] [Related]
2. Adherence to Adjuvant Endocrine Therapy in Insured Black and White Breast Cancer Survivors: Exploring Adherence Measures in Patient Data.
Sheppard VB; He J; Sutton A; Cromwell L; Adunlin G; Salgado TM; Tolsma D; Trout M; Robinson BE; Edmonds MC; Bosworth HB; Tadesse MG
J Manag Care Spec Pharm; 2019 May; 25(5):578-586. PubMed ID: 31039059
[TBL] [Abstract][Full Text] [Related]
3. Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer.
Farias AJ; Du XL
J Clin Oncol; 2017 Jan; 35(1):86-95. PubMed ID: 28034069
[TBL] [Abstract][Full Text] [Related]
4. The Association Between Out-of-Pocket Costs and Adherence to Adjuvant Endocrine Therapy Among Newly Diagnosed Breast Cancer Patients.
Farias AJ; Hansen RN; Zeliadt SB; Ornelas IJ; Li CI; Thompson B
Am J Clin Oncol; 2018 Jul; 41(7):708-715. PubMed ID: 27893470
[TBL] [Abstract][Full Text] [Related]
5. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
Cavazza M; Banks H; Ercolanoni M; Cukaj G; Bianchi G; Capri G; Longo F
Breast Cancer Res Treat; 2020 Aug; 183(1):189-199. PubMed ID: 32591986
[TBL] [Abstract][Full Text] [Related]
6. Examination of the Link Between Medication Adherence and Use of Mail-Order Pharmacies in Chronic Disease States.
Fernandez EV; McDaniel JA; Carroll NV
J Manag Care Spec Pharm; 2016 Nov; 22(11):1247-1259. PubMed ID: 27783552
[TBL] [Abstract][Full Text] [Related]
7. Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data.
Lailler G; Memoli V; Le Bihan Benjamin C; Ben Diane MK; Lauzier S; Mancini J; Bousquet PJ; Bouhnik AD
Clin Breast Cancer; 2021 Aug; 21(4):e415-e426. PubMed ID: 33745868
[TBL] [Abstract][Full Text] [Related]
8. Racial differences in long-term adjuvant endocrine therapy adherence and mortality among Medicaid-insured breast cancer patients in Texas: Findings from TCR-Medicaid linked data.
Farias AJ; Wu WH; Du XL
BMC Cancer; 2018 Dec; 18(1):1214. PubMed ID: 30514270
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
Gil JM; Rubio-Terrés C; Del Castillo A; González P; Canorea F
Clin Transl Oncol; 2006 May; 8(5):339-48. PubMed ID: 16760009
[TBL] [Abstract][Full Text] [Related]
10. Race and Patient-reported Symptoms in Adherence to Adjuvant Endocrine Therapy: A Report from the Women's Hormonal Initiation and Persistence Study.
Sheppard VB; Sutton AL; Hurtado-de-Mendoza A; He J; Dahman B; Edmonds MC; Hackney MH; Tadesse MG
Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):699-709. PubMed ID: 33514603
[TBL] [Abstract][Full Text] [Related]
11. The Influence of a Community Pharmacy Automatic Prescription Refill Program on Medicare Part D Adherence Metrics.
Lester CA; Mott DA; Chui MA
J Manag Care Spec Pharm; 2016 Jul; 22(7):801-7. PubMed ID: 27348281
[TBL] [Abstract][Full Text] [Related]
12. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer.
Sedjo RL; Devine S
Breast Cancer Res Treat; 2011 Jan; 125(1):191-200. PubMed ID: 20495864
[TBL] [Abstract][Full Text] [Related]
13. Adherence to Adjuvant Endocrine Therapy and Survival Among Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer.
Park C; Heo JH; Mehta S; Han S; Spencer JC
Clin Drug Investig; 2023 Mar; 43(3):167-176. PubMed ID: 36740664
[TBL] [Abstract][Full Text] [Related]
14. Impact of Patient Reimbursement Timing and Patient Out-of-Pocket Expenses on Medication Adherence in Patients Covered by Private Drug Insurance Plans.
Després F; Forget A; Kettani FZ; Blais L
J Manag Care Spec Pharm; 2016 May; 22(5):539-47. PubMed ID: 27123915
[TBL] [Abstract][Full Text] [Related]
15. Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women.
Artignan J; Capmas P; Panjo H; Constantinou P; Pelletier-Fleury N
BMC Med; 2023 Nov; 21(1):463. PubMed ID: 38001491
[TBL] [Abstract][Full Text] [Related]
16. Association of Endocrine Therapy Initiation Timeliness With Adherence and Continuation in Low-Income Women With Breast Cancer.
Sood N; Liu Y; Lian M; Greever-Rice T; Lucht J; Schmaltz C; Colditz GA
JAMA Netw Open; 2022 Aug; 5(8):e2225345. PubMed ID: 35921108
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapy use among Appalachian breast cancer survivors.
Tan X; Marshall VD; Anderson RT; Donohoe J; Camacho F; Balkrishnan R
Medicine (Baltimore); 2015 Jul; 94(26):e1071. PubMed ID: 26131828
[TBL] [Abstract][Full Text] [Related]
18. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
[TBL] [Abstract][Full Text] [Related]
19. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases.
Lambert-Côté L; Bouhnik AD; Bendiane MK; Bérenger C; Mondor M; Huiart L; Lauzier S
Breast Cancer Res Treat; 2020 Apr; 180(3):777-790. PubMed ID: 32086655
[TBL] [Abstract][Full Text] [Related]
20. Association between financial burden and adjuvant hormonal therapy adherence and persistent use for privately insured women aged 18-64 years in BCBS of Texas.
Kim J; Rajan SS; Du XL; Franzini L; Giordano SH; Morgan RO
Breast Cancer Res Treat; 2018 Jun; 169(3):573-586. PubMed ID: 29423900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]